Guardant Health, Redwood City, Calif, is collaborating with Janssen Biotech, Horsham, Pa, to pursue regulatory approval and commercialization of the Guardant360 CDx as a companion diagnostic for amivantamab, an investigational EGFR-MET bispecific antibody being studied in the treatment of non-small cell lung cancer (NSCLC). The agreement covers the United States, Canada, Japan, and Europe. “Studies continue to show that the full promise of personalized medicine remains out of reach for the majority of patients with advanced non-small cell lung cancer who are not receiving complete genotyping before starting therapy, thus impeding their treatment with the most appropriate therapy,” says AmirAli Talasaz, PhD, Guardant Health president. “Our Guardant360 liquid biopsy has been shown to overcome the barriers associated with tissue and increase genotyping rates, which we believe will ultimately help ensure that all patients who are eligible for potentially life-changing therapies are identified from the start.” The Guardant360 blood test is increasingly being used to guide treatment in metastatic cancer, as the number of treatment-relevant genomic alterations continues to grow. Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from patient blood samples. The Guardant360 test is broadly covered by Medicare for use across the vast majority of advanced solid tumors, including patients with metastatic NSCLC. For more information, visit Guardant Health.
